In the article, “A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?”,[1] which appeared in Volume 97, Issue 30 of Medicine, several corrections need to be noted based on corrections to the hazard ratios (HR) and confidence intervals (CI) for the subgroup of men, non-Asians, smokers and Del19 mutations with new ln-derived values. This evidence concerns the gene EGFR and lung cancer.